Pt got 1st dose of vaccine and developed skin rash on injection site approximately 2 weeks later; it is very itchy and red; it is very itchy and red; This spontaneous case was reported by a nurse (subsequently medically confirmed) and describes the occurrence of VACCINATION SITE RASH (Pt got 1st dose of vaccine and developed skin rash on injection site approximately 2 weeks later), VACCINATION SITE PRURITUS (it is very itchy and red) and VACCINATION SITE ERYTHEMA (it is very itchy and red) in a 76-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 031M20A) for COVID-19 vaccination.     Concomitant products included ATENOLOL, LOSARTAN, ACETYLSALICYLIC ACID (ASPIRIN (E.C.)), CALCIUM, ASCORBIC ACID, ERGOCALCIFEROL, NICOTINAMIDE, RETINOL PALMITATE, RIBOFLAVIN, THIAMINE MONONITRATE (MULTIVITAMIN 6), ASCORBIC ACID (VITAMIN C [ASCORBIC ACID]), ROSUVASTATIN, FAMOTIDINE and BUDESONIDE, FORMOTEROL FUMARATE (SYMBICORT) for an unknown indication.    On 10-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 22-Feb-2021, the patient experienced VACCINATION SITE RASH (Pt got 1st dose of vaccine and developed skin rash on injection site approximately 2 weeks later), VACCINATION SITE PRURITUS (it is very itchy and red) and VACCINATION SITE ERYTHEMA (it is very itchy and red). The patient was treated with HYDROCORTISONE at an unspecified dose and frequency and LORATADINE (CLARITIN [LORATADINE]) at an unspecified dose and frequency. At the time of the report, VACCINATION SITE RASH (Pt got 1st dose of vaccine and developed skin rash on injection site approximately 2 weeks later), VACCINATION SITE PRURITUS (it is very itchy and red) and VACCINATION SITE ERYTHEMA (it is very itchy and red) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Reported concomitant medication including Nebulizer treatment. This case was received via an unknown source (no reference has been entered for a health authority or license partner) on 26-Feb-2021 and was forwarded to Moderna on 26-Feb-2021.    This spontaneous case was reported by a nurse (subsequently medically confirmed) and describes the occurrence of VACCINATION SITE RASH (Pt got 1st dose of vaccine and developed skin rash on injection site approximately 2 weeks later), VACCINATION SITE PRURITUS (it is very itchy and red) and VACCINATION SITE ERYTHEMA (it is very itchy and red) in a 76-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 031M20A) for COVID-19 vaccination.     Concomitant products included ATENOLOL, LOSARTAN, ACETYLSALICYLIC ACID (ASPIRIN (E.C.)), CALCIUM, ASCORBIC ACID, ERGOCALCIFEROL, NICOTINAMIDE, RETINOL PALMITATE, RIBOFLAVIN, THIAMINE MONONITRATE (MULTIVITAMIN 6), ASCORBIC ACID (VITAMIN C [ASCORBIC ACID]), ROSUVASTATIN, FAMOTIDINE and BUDESONIDE, FORMOTEROL FUMARATE (SYMBICORT) for an unknown indication.    On 10-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 22-Feb-2021, the patient experienced VACCINATION SITE RASH (Pt got 1st dose of vaccine and developed skin rash on injection site approximately 2 weeks later), VACCINATION SITE PRURITUS (it is very itchy and red) and VACCINATION SITE ERYTHEMA (it is very itchy and red). The patient was treated with HYDROCORTISONE at an unspecified dose and frequency and LORATADINE (CLARITIN [LORATADINE]) at an unspecified dose and frequency. At the time of the report, VACCINATION SITE RASH (Pt got 1st dose of vaccine and developed skin rash on injection site approximately 2 weeks later), VACCINATION SITE PRURITUS (it is very itchy and red) and VACCINATION SITE ERYTHEMA (it is very itchy and red) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Reported concomitant medication including Nebulizer treatment.